Investigators conducted a retrospective review that spanned 10 years with the goals of describing the clinical ...

Dr. Tycel Phillips discusses the FDA approval of a Calquence combo in MCL, making it the first and only BTK inhibitor ...

Disparate pathogenic mechanisms complicate precision-medicine efforts to treat diffuse large B-cell lymphoma (DLBCL), the most common lymphoma diagnosis. Though potentially curable with frontline ...

Suzhou Genhouse Bio Co. Ltd. has disclosed tyrosine-protein phosphatase non-receptor type 11 (PTPN11; PTP-2C; SHP-2) inhibitors reported to be useful for the treatment of cancer, Noonan syndrome and ...

Investigative therapies to treat moderate to severe plaque psoriasis in clinical trials include several orally administered ...

Panelists discuss how decisions to switch between Bruton tyrosine kinase (BTK) inhibitors are driven by multiple factors including intolerable toxicities, development of resistance mutations, disease ...

The drug received accelerated approval in October 2017 as monotherapy for adults with MCL who have received at least one ...

Panelists discuss how challenges in implementing emerging Bruton tyrosine kinase inhibitor (BTKi) regimens for ...

Xi’an Xintong Medicine Research Co. Ltd. has synthesized tyrosine-protein kinase JAK3 inhibitors reported to be useful for the treatment of rheumatoid arthritis, alopecia areata, vitiligo, asthma, ...

Patients with EGFR-mutated non-small cell lung cancer treated with osimertinib experienced more cancer therapy-related ...

Patients are significantly more likely to experience treatment-related cardiac events with osimertinib than with other EGFR TKIs, data suggest.